These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37239772)

  • 1. Systematic Review of the Apomorphine Challenge Test in the Assessment of Dopaminergic Activity in Schizophrenia.
    Duval F
    Healthcare (Basel); 2023 May; 11(10):. PubMed ID: 37239772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders.
    Duval F; Mokrani MC; Erb A; Danila V; Gonzalez Lopera F; Jeanjean L
    Front Psychiatry; 2020; 11():533872. PubMed ID: 33101075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests.
    Duval F; Mokrani MC; Monreal J; Bailey P; Valdebenito M; Crocq MA; Macher JP
    Psychoneuroendocrinology; 2003 Jul; 28(5):627-42. PubMed ID: 12727131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in multihormonal responses to the dopamine agonist apomorphine between unipolar and bipolar depressed patients.
    Monreal JA; Duval F; Mokrani MC; Fattah S; Palao D
    J Psychiatr Res; 2019 May; 112():18-22. PubMed ID: 30836201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.
    Duval F; Mokrani MC; Macher JP; Crocq MA; Castro JO; Bailey P; Lataste X
    Psychopharmacology (Berl); 1993; 110(1-2):177-80. PubMed ID: 7870880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multihormonal responses to apomorphine in mental illness.
    Mokrani MC; Duval F; Crocq MA; Bailey PE; Macher JP
    Psychoneuroendocrinology; 1995; 20(4):365-75. PubMed ID: 8532820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine in the evaluation of dopaminergic function in man.
    Lal S
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):117-64. PubMed ID: 3290992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent prolactin and pituitary-adrenal activity in rats selectively bred for different dopamine responsiveness.
    Rots NY; Cools AR; Oitzl MS; de Jong J; Sutanto W; de Kloet ER
    Endocrinology; 1996 May; 137(5):1678-86. PubMed ID: 8612501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of tolerance of dopaminergic responses in man.
    Lal S; Thavundayil JX; Ng Ying Kin NM; Dai X; Schwartz G; Montoya A
    J Neural Transm (Vienna); 2008 Aug; 115(8):1189-98. PubMed ID: 18506387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine measures of dopaminergic function in chronic cocaine users.
    Lee MA; Bowers MM; Nash JF; Meltzer HY
    Psychiatry Res; 1990 Aug; 33(2):151-9. PubMed ID: 2243892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression.
    McPherson H; Walsh A; Silverstone T
    J Affect Disord; 2003 Sep; 76(1-3):121-5. PubMed ID: 12943941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
    Rotrosen J; Angrist B; Gershon S; Paquin J; Branchey L; Oleshansky M; Halpern F; Sachar EJ
    Br J Psychiatry; 1979 Nov; 135():444-56. PubMed ID: 540209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
    Kolakowska T; Gelder M; Fraser S
    Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation.
    Brambilla F; Bellodi L; Perna G; Arancio C; Bertani A
    Biol Psychiatry; 1997 Nov; 42(10):889-97. PubMed ID: 9359974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin studies in normals: implications for clinical research.
    Cohen MR
    Psychiatry Res; 1983 Apr; 8(4):299-310. PubMed ID: 6576396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of some peptides on dopaminergic function in man.
    Lal S; Nair NP; Isaac I; Thavundayil J; Guyda H
    J Neural Transm Suppl; 1990; 29():173-81. PubMed ID: 2113567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP; Simpkins J; Meites J; Moore KE
    Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hydrocortisone on basal and apomorphine-induced growth hormone secretion in normal subjects.
    Lal S; Nair NP; Isaac I; Guyda H; Quirion R
    Clin Invest Med; 1988 Jun; 11(3):218-23. PubMed ID: 3402107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noradrenergic and dopaminergic interrelation in schizophrenia.
    Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
    Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.